Szemészet, 2019 (156. évfolyam, 1-4. szám)
2019-05-01 / Suplementum I.
Kongresszusi összefoglalók ES4 SOE LECTURE: Local interferon alpha-2b therapy of ocular surface neoplasias Eszter Szalai University of Debrecen, Ophthalmology Clinic, Debrecen Aims: To present our experience and practice with local interferon (INF) alpha-lb immunotherapy in ocular surface neoplasia. Methods: Loca! INF alfa-Zb is initiated upon National Institute of Pharmacy and Nutrition approval in patients with certain types of conjunctival and corneal tumors. Histology proven invasive squamous carcinoma is an exclusion criterion for the local treatment. INF eyedrop and injection is prepared by the University Pharmacy from a multidose INF injection (IntronA 30 million IU, MSD Hungary). Based on size and corneal involvement of the lesion, patients are started on eyedrops and subconjunctival (perilesional) INF alpha-lb injection. The duration of treatment depends on resolution of the tumor. A comprehensive ophthalmic examination is performed every second week when regression of the tumor is registered and treatment-related complaints of the patients were recorded. Cytologica! atypia and extent of the lesion is documented with in vivo confocal microscopy. Results: 8 patients (mean age: 66.38±17-57 years) were treated with local INF alpha-Zb, Z patients had intraepithelial dysplasia, Z patients had squamous papilloma, 4 patients had carcinoma in situ. All patients were started on INF alpha-Zb eyedrops and 6 patients received subconjunctival injection too. The tumor size decreased at the first month of treatment in all cases. The mean time to tumor resolution was i.40±1.08 months. In two patients, there was a complete resolution after two weeks of the first injection. Tumor regression obtained by slit lamp showed a correlation with morphological changes observed by confocal microscopy. No major local or systemic side effect was reported during the treatment. Conclusions: Based on our experiences, local INF alpha-Zb is a safe and effective treatment for de novo and recurred ocular surface neoplasias or for lesions that were excised with positive surgical margins. ES5 It’s Uveitis. What next? A hitchhiker’s guide through the uveitis galaxy work-up Francesco Pichi Cleveland Clinic Abu Dhabi This section will address the laboratory and imaging work up needed to correctly diagnose uveitis entities and appropriately treat them. Through clinical cases the audience will learn how to tailor a uveitis work-up according to different presentations, how to minimize non-necessary tests that can misguide the diagnosis and increase the expenses. ES6 Inflammation or infection? How to get it right Gabor Deak Medical University Vienna The most important decision in the workup of a uveitis patient is the decision whether the inflammation is caused by an infection or not, since this changes the whole further management of the patient. However this is often one of the most challenging decision to make. We will assess the clinical and laboratory findings that might be of help in making the right diagnosis. E27 Muiitimodal imaging- When? What? Where? The Ophthalmologists little helper Tünde Pető, Marion Munk Department of Ophthalmology, Queen’s University Belfast, Northern Ireland Multimodal imaging is nowadays indispensable in daily clinic and it is essentia1 for the assessment and follow up of uveitis patients. This presentation will focus on the application of current image modalities to help assess and follow-up patients with uveitis. ESS Which treatment? - and When? - Tailor new emerging treatment modalities in uveitis Avinash Gurbaxani Moorfields Eye Hospital Dubai This talk will cover treatment principles and will aim to educate the listener on the new drugs available in uveits and when and how to use them with clinical examples. ESS Late complications of uveitis - a never ending story Shiri Shulman Tel Aviv Medical Eye center and Ophthalmology Institute at Assuta Medical Centers The talk will cover the common late complications such as cataract, glaucoma and CNV and will include diagnosis and treatment. We will also discuss special considerations regarding cataract operation in uveitis patients. E3C The uveitis grails quest - discussion '32'; \ /
